Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31448649 | 0.86 | SLC6A4 (0.43) | MEN1HTTKMT2ASLC6A4HTR2A | |
| SCHEMBL30772398 | 0.85 | MEN1 (0.35) | MEN1HTTKMT2ASLC6A4HTR2A | |
| SCHEMBL30772390 | 0.81 | HTR2A (0.34) | MEN1HTTKMT2ASLC6A4HTR2A | |
| SCHEMBL30772388 | 0.81 | HTR2A (0.33) | MEN1HTTKMT2ASLC6A4HTR2A | |
| SCHEMBL30772381 | 0.80 | SLC6A4 (0.39) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL31448613 | 0.78 | P2RX3 (0.34) | P2RX3P2RX2 | |
| SCHEMBL31448527 | 0.77 | L3MBTL1 (0.47) | MEN1HTTKMT2ASLC6A4KCNH2 | |
| SCHEMBL31448448 | 0.77 | ALDH1A1 (0.43) | MEN1KMT2ASLC6A4HTR2AKCNH2 | |
| SCHEMBL30772377 | 0.75 | L3MBTL1 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL30772401 | 0.72 | L3MBTL1 (0.35) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4512801-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | Kissei Pharmaceutical Co., Ltd. (JP) | 2025-02-26 | — | — | EP | disclosed |
| CN-119343332-A | 3, 4-Dihydro-quinolin-2 (1H) -one compounds | 橘生药品工业株式会社 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024005113-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | キッセイ薬品工業株式会社 | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | TSHR, TRHR, GHSR | MEN1 90/4885HTT 1431/4885KMT2A 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.